Brainstorm Cell Therapeutics Inc. SEC filings BCLI
Brainstorm Cell Therapeutics Inc. has 949 filings in SEC EDGAR's recent list, going back to May 24, 2001. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| DEF 14A | Proxy statement | May 16, 2025 | Jun 25, 2025 |
| PRE 14A | Preliminary proxy statement | May 6, 2025 | May 6, 2025 |
| DEF 14A | Proxy statement | Aug 16, 2024 | Sep 16, 2024 |
| PRE 14A | Preliminary proxy statement | Aug 5, 2024 | Sep 16, 2024 |
| DEFA14A | Additional proxy material | Nov 22, 2023 | — |
| DEF 14A | Proxy statement | Nov 8, 2023 | Dec 18, 2023 |
| DEF 14A | Proxy statement | Dec 13, 2022 | Jan 10, 2023 |
| DEF 14A | Proxy statement | Nov 4, 2021 | Dec 14, 2021 |
| DEF 14A | Proxy statement | Oct 1, 2020 | Nov 10, 2020 |
| DEF 14A | Proxy statement | Oct 25, 2019 | Dec 11, 2019 |
| DEF 14A | Proxy statement | Oct 10, 2018 | Nov 29, 2018 |
| DEF 14A | Proxy statement | Sep 14, 2017 | Nov 9, 2017 |
| DEF 14A | Proxy statement | May 11, 2016 | Jun 21, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 22, 2016 | Apr 22, 2016 |
| DEF 14A | Proxy statement | Jul 17, 2015 | Aug 26, 2015 |
| PRE 14A | Preliminary proxy statement | Jul 1, 2015 | Aug 26, 2015 |
| DEF 14A | Proxy statement | Jul 22, 2014 | Aug 14, 2014 |
| PRE 14A | Preliminary proxy statement | Jul 10, 2014 | Jul 10, 2014 |
| DEF 14A | Proxy statement | Mar 15, 2013 | Apr 18, 2013 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2013 | Mar 4, 2013 |
| DEF 14A | Proxy statement | May 7, 2012 | Jun 12, 2012 |
| DEF 14A | Proxy statement | Apr 29, 2011 | Jun 9, 2011 |
| DEF 14A | Proxy statement | Apr 30, 2010 | May 26, 2010 |
| DEF 14A | Proxy statement | Apr 29, 2008 | Jun 5, 2008 |
| DEF 14A | Proxy statement | Nov 20, 2006 | Dec 18, 2006 |
| PRE 14A | Preliminary proxy statement | Nov 8, 2006 | Nov 8, 2006 |
| DEF 14A | Proxy statement | Aug 22, 2006 | Sep 20, 2006 |
| PRE 14A | Preliminary proxy statement | Aug 11, 2006 | Sep 20, 2006 |
| DEF 14A | Proxy statement | Mar 1, 2005 | Mar 28, 2005 |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCLI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1137883
- Former names
- BRAINSTORM CELL THERAPEUTICS INC (until Jul 23, 2012); GOLDEN HAND RESOURCES INC (until Nov 22, 2004); WIZBANG TECHNOLOGIES INC (until Aug 8, 2003)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.